Education
About Us
Working with TipRanks
Follow Us
Invivyd (IVVD)
NASDAQ:IVVD
IVVD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.35 - $4.74
Previous CloseN/A
Volume606.77K
Average Volume (3M)6.49M
Market Cap
$88.53M
Enterprise Value$16.65M
Total Cash (Recent Filing)$200.64M
Total Debt (Recent Filing)$2.17M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
May 08, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.43
Shares Outstanding119,961,450
10 Day Avg. Volume2,361,016
30 Day Avg. Volume6,492,408
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.63
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.21
Enterprise Value/Ebitda-0.07
Forecast
1Y Price Target
$10.00Price Target Upside1251.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Invivyd News
---
Bulls Say, Bears Say
Bulls Say
Clinical DataInvivyd announced positive Phase 3 long-term exploratory clinical data demonstrating robust protection from symptomatic COVID-19 with PEMGARDA.
Financial PerformanceManagement highlights a 48% increase in PEMGARDA revenues, driven by growing demand from healthcare providers.
Product PerformancePEMGARDA continues to serve as the cornerstone for COVID-19 prophylaxis in a high–unmet need population.
Bears Say
Market ChallengesThe slower-than-expected growth of PEMGARDA sales was due to confusion among healthcare providers regarding its antiviral activity.
Regulatory ChallengesThe FDA has rejected Invivyd’s submission to expand PEMGARDA's Emergency Use Authorization to include COVID-19 treatment for certain immunocompromised patients.
Sales PerformanceIVVD reported 3Q24 Pemgarda net product revenue of $9.3mn, coming in well short of consensus at $32mn.
---
Ownership Overview
13.41% Insiders
7.58% Mutual Funds
44.54% Other Institutional Investors
27.95% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IVVD FAQ
What was Invivyd’s price range in the past 12 months?
Invivyd lowest stock price was $0.35 and its highest was $4.74 in the past 12 months.
What is Invivyd’s market cap?
Invivyd’s market cap is $88.53M.
When is Invivyd’s upcoming earnings report date?
Invivyd’s upcoming earnings report date is May 08, 2025 which is in 44 days.
How were Invivyd’s earnings last quarter?
Invivyd released its earnings results on Mar 20, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.05.
Is Invivyd overvalued?
According to Wall Street analysts Invivyd’s price is currently Undervalued.
Does Invivyd pay dividends?
Invivyd does not currently pay dividends.
What is Invivyd’s EPS estimate?
Invivyd’s EPS estimate is -0.03.
How many shares outstanding does Invivyd have?
Invivyd has 119,961,450 shares outstanding.
What happened to Invivyd’s price movement after its last earnings report?
Invivyd reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went up 2.778%.
Which hedge fund is a major shareholder of Invivyd?
Currently, no hedge funds are holding shares in IVVD
---
Invivyd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (1251.35% Upside)
$10.00 (1251.35% Upside)
Blogger Sentiment
Bullish
IVVD Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $293.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-76.11%
12-Months-Change
Fundamentals
Return on Equity
-138.71%
Trailing 12-Months
Asset Growth
-43.49%
Trailing 12-Months
Company Description
Invivyd
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
---
IVVD Company Deck
---
IVVD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment with significant achievements in clinical results and product growth being overshadowed by commercial headwinds and the withdrawal of revenue guidance.Read More>---
IVVD Stock 12 Month Forecast
Average Price Target
$10.00
▲(1251.35% Upside)
Technical Analysis
Best Analysts Covering IVVD
1 Year
1 Year Success Rate
2/15 ratings generated profit
1 Year Average Return
-29.87%
reiterated a buy rating 28 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 13.33% of your transactions generating a profit, with an average return of -29.87% per trade.
---